Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer

Kazuyoshi Yamamoto, Yoshiyuki Fujiwara, Toshiro Nishida, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate the feasibility and efficacy of modified triplet chemotherapy with docetaxel, 5-fluorouracil and cisplatin as induction chemotherapy for advanced gastric cancer (AGC). Patients and Methods: Treatment-naive patients with AGC were eligible. The regimen consisted of 350 mg/m2/day 5-FU by continuous infusion on days 1 to 5, 10 mg/m2/day CDDP intravenously on days 1 to 5, and docetaxel at 60 mg/m2/day intravenously on day 1. After 2 cycles (each cycle consisted of 4 weeks), surgical resection was attempted, 2-4 weeks after the completion of the regimen. Results: Eighteen patients were enrolled. Adverse events included grade 3 anorexia and nausea in 16.7% and 11.1% and grade 4 leukocytopenia and neutropenia in 5.6% and 27.8%, respectively. The overall response rate was 44.4%. Surgery was conducted in 15 patients. The 1- and 3-year survival rates were 75.6% and 51.1%, respectively. Conclusion: The modified triplet combination therapy is effective and well tolerated by patients with AGC.

Original languageEnglish
Pages (from-to)4211-4215
Number of pages5
JournalAnticancer Research
Volume29
Issue number10
Publication statusPublished - Oct 1 2009
Externally publishedYes

Fingerprint

docetaxel
Isoflurophate
Induction Chemotherapy
Fluorouracil
Stomach Neoplasms
Leukopenia
Anorexia
Neutropenia
Nausea
Cisplatin
Survival Rate
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yamamoto, K., Fujiwara, Y., Nishida, T., Takiguchi, S., Nakajima, K., Miyata, H., ... Doki, Y. (2009). Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. Anticancer Research, 29(10), 4211-4215.

Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. / Yamamoto, Kazuyoshi; Fujiwara, Yoshiyuki; Nishida, Toshiro; Takiguchi, Shuji; Nakajima, Kiyokazu; Miyata, Hiroshi; Yamasaki, Makoto; Mori, Masaki; Doki, Yuichiro.

In: Anticancer Research, Vol. 29, No. 10, 01.10.2009, p. 4211-4215.

Research output: Contribution to journalArticle

Yamamoto, K, Fujiwara, Y, Nishida, T, Takiguchi, S, Nakajima, K, Miyata, H, Yamasaki, M, Mori, M & Doki, Y 2009, 'Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer', Anticancer Research, vol. 29, no. 10, pp. 4211-4215.
Yamamoto K, Fujiwara Y, Nishida T, Takiguchi S, Nakajima K, Miyata H et al. Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. Anticancer Research. 2009 Oct 1;29(10):4211-4215.
Yamamoto, Kazuyoshi ; Fujiwara, Yoshiyuki ; Nishida, Toshiro ; Takiguchi, Shuji ; Nakajima, Kiyokazu ; Miyata, Hiroshi ; Yamasaki, Makoto ; Mori, Masaki ; Doki, Yuichiro. / Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. In: Anticancer Research. 2009 ; Vol. 29, No. 10. pp. 4211-4215.
@article{6482d6cfe67047a6996bc6a970eab0a5,
title = "Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer",
abstract = "Background: The aim of this study was to evaluate the feasibility and efficacy of modified triplet chemotherapy with docetaxel, 5-fluorouracil and cisplatin as induction chemotherapy for advanced gastric cancer (AGC). Patients and Methods: Treatment-naive patients with AGC were eligible. The regimen consisted of 350 mg/m2/day 5-FU by continuous infusion on days 1 to 5, 10 mg/m2/day CDDP intravenously on days 1 to 5, and docetaxel at 60 mg/m2/day intravenously on day 1. After 2 cycles (each cycle consisted of 4 weeks), surgical resection was attempted, 2-4 weeks after the completion of the regimen. Results: Eighteen patients were enrolled. Adverse events included grade 3 anorexia and nausea in 16.7{\%} and 11.1{\%} and grade 4 leukocytopenia and neutropenia in 5.6{\%} and 27.8{\%}, respectively. The overall response rate was 44.4{\%}. Surgery was conducted in 15 patients. The 1- and 3-year survival rates were 75.6{\%} and 51.1{\%}, respectively. Conclusion: The modified triplet combination therapy is effective and well tolerated by patients with AGC.",
author = "Kazuyoshi Yamamoto and Yoshiyuki Fujiwara and Toshiro Nishida and Shuji Takiguchi and Kiyokazu Nakajima and Hiroshi Miyata and Makoto Yamasaki and Masaki Mori and Yuichiro Doki",
year = "2009",
month = "10",
day = "1",
language = "English",
volume = "29",
pages = "4211--4215",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer

AU - Yamamoto, Kazuyoshi

AU - Fujiwara, Yoshiyuki

AU - Nishida, Toshiro

AU - Takiguchi, Shuji

AU - Nakajima, Kiyokazu

AU - Miyata, Hiroshi

AU - Yamasaki, Makoto

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Background: The aim of this study was to evaluate the feasibility and efficacy of modified triplet chemotherapy with docetaxel, 5-fluorouracil and cisplatin as induction chemotherapy for advanced gastric cancer (AGC). Patients and Methods: Treatment-naive patients with AGC were eligible. The regimen consisted of 350 mg/m2/day 5-FU by continuous infusion on days 1 to 5, 10 mg/m2/day CDDP intravenously on days 1 to 5, and docetaxel at 60 mg/m2/day intravenously on day 1. After 2 cycles (each cycle consisted of 4 weeks), surgical resection was attempted, 2-4 weeks after the completion of the regimen. Results: Eighteen patients were enrolled. Adverse events included grade 3 anorexia and nausea in 16.7% and 11.1% and grade 4 leukocytopenia and neutropenia in 5.6% and 27.8%, respectively. The overall response rate was 44.4%. Surgery was conducted in 15 patients. The 1- and 3-year survival rates were 75.6% and 51.1%, respectively. Conclusion: The modified triplet combination therapy is effective and well tolerated by patients with AGC.

AB - Background: The aim of this study was to evaluate the feasibility and efficacy of modified triplet chemotherapy with docetaxel, 5-fluorouracil and cisplatin as induction chemotherapy for advanced gastric cancer (AGC). Patients and Methods: Treatment-naive patients with AGC were eligible. The regimen consisted of 350 mg/m2/day 5-FU by continuous infusion on days 1 to 5, 10 mg/m2/day CDDP intravenously on days 1 to 5, and docetaxel at 60 mg/m2/day intravenously on day 1. After 2 cycles (each cycle consisted of 4 weeks), surgical resection was attempted, 2-4 weeks after the completion of the regimen. Results: Eighteen patients were enrolled. Adverse events included grade 3 anorexia and nausea in 16.7% and 11.1% and grade 4 leukocytopenia and neutropenia in 5.6% and 27.8%, respectively. The overall response rate was 44.4%. Surgery was conducted in 15 patients. The 1- and 3-year survival rates were 75.6% and 51.1%, respectively. Conclusion: The modified triplet combination therapy is effective and well tolerated by patients with AGC.

UR - http://www.scopus.com/inward/record.url?scp=71949119289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71949119289&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 4211

EP - 4215

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -